Study on the efficacy and safety of vericygide in patients with heart failure

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300077292

Enrollment

Unknown

Registered

2023-11-03

Start date

2023-08-01

Completion date

Unknown

Last updated

2023-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure

Interventions

Vericiguat group:None

Without vericiguat group:None

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Symptomatic chronic heart failure adult patients with stable ejection fraction reduction following recent heart failure decompensation via intravenous therapy

Exclusion criteria

Exclusion criteria: ? In addition to heart-related diseases, patients with other diseases that limit their expected survival to less than 6 months, including active malignancies; ? Severe renal insufficiency, eGFR < 20ml/min or undergoing hemofiltration or dialysis treatment; ? Severe liver insufficiency; ? Pregnant and lactating women or patients who plan to become pregnant in the near future; ?Unable to cooperate with or refuse follow-up.

Design outcomes

Primary

Measure	Time frame
Left ventricular ejection fraction;NT-proBNP;	—

Secondary

Measure	Time frame
Cardiac death;Re-hospitalization for heart failure;Major adverse cardiovascular events;Creatinine;Serum potassium;Blood pressure change;	—

Countries

China

Contacts

Public ContactSi Daoyuan

China-Japan Union Hospital of Jilin University

sidaoyuan@jlu.edu.cn+86 135 7894 9866

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026